Gejl, Michael
Brock, Birgitte
Egefjord, Lærke
Vang, Kim
Rungby, Jørgen
Gjedde, Albert http://orcid.org/0000-0002-3756-7401
Article History
Received: 16 March 2017
Accepted: 29 November 2017
First Online: 13 December 2017
Competing Interests
: M. Gejl: None. B. Brock: Board Member; Author; Allergan, Inc., Novo Nordisk A/S. Research Support. Speaker’s Bureau; Pfizer Inc. L. Egefjord: None. K. Vang: None J. Rungby: Advisory Panel; Merck & Co., Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi U.S.. Employee; Spouse/Partner; Novo Nordisk A/S. Research Support; Novo Nordisk A/S, Eli Lilly and Company, Amylin Pharmaceuticals, LLC. Speaker’s Bureau; Merck & Co., Inc., Novo Nordisk A/S, Johnson & Johnson, Sanofi U.S., AstraZeneca/Bristol-Myers Squibb. A. Gjedde: Advisory panel; Executive Council, European Dana Alliance for the Brain, European Research Council. Consultant; National Expert, Horizon2020 SC1 PC Health, European Commission, Novo-Nordisk A/S. Research support; Danish Council of Independent Research, National Institutes of Health BRAIN Initiative. Speaker’s bureau; MINDexult. Stocks/shareholder; Danske Bank.